 |
Christopher Haqq, MD, PhD
Biographical Sketch
| BS, 1987, Stanford University,
Palo Alto, CA, Biological Sciences |
| MD, 1996, Harvard Medical School, Boston,
MA, Medicine |
| PhD, 1996, Harvard Graduate
School of Arts and Sciences. Cambridge, MA, Genetics |
Internal Medicine Residency, 1998, University
of California, San Francisco, CA |
Oncology Fellowship, 2001,
University of California, San Francisco,
CA |
| Molecular Medicine
Fellowship, 2001, University of California, San Francisco,
CA |
|
|
|
| 2001-2005 |
Assistant Adjunct Professor of Medicine – University
of California San Francisco |
2005-present |
Assistant Adjunct Professor of Urology, University of
California, San Francisco |
2005-2006 |
Associate Director,Early Development Oncology, Amgen
Inc., Thousand Oaks, CA |
2006-2007 |
Director Medical Sciences, Early Development Oncology
, Amgen Inc., Thousand Oaks, CA |
| 2007-present |
Senior Director, Clinical Research and Development,
Cougar Biotechnology Inc., Los Angeles, CA |
Christopher Haqq, MD, PhD, studied medicine and genetics concurrently
at Harvard Medical School, and he received his MD and PhD degrees
in 1996. He then joined UCSF for internship and residency in
internal medicine at UCSF, and fellowship in medical oncology.
Haqq joined the Department of Medicine in 2001, and his June
2005 appointment in the Department of Urology formalizes his
ongoing involvement with the Prostate Cancer Center. Haqq collaborates
with Peter Carroll, MD, MPH and June Chan, ScD, on a prostate cancer
clinical research study, the Molecular Effects of Nutrition Supplements
(MENS) study. MENS is a placebo-controlled, blinded intervention
study of lycopene, fish oil versus placebo olive oil in men with
favorable-risk prostate cancer. He is specifically interested
in the use of expression array technology to uncover new pathways
responding to nutrient and dietary influences in prostate cancer.
In addition to his appointment at UCSF, Haqq works at Cougar
Biotechnology in Los Angeles, California, where he is involved
in early development of new targeted biologic therapies.
return
to top
|
|
|
|
|
|
